Reuters -- Takeda Pharmaceutical, Japan’s top drugmaker, kept its full-year profit outlook unchanged despite larger-than-forecast first half earnings, as it expects yen strength and weak sales to dull the impact of cost cuts.
Reuters -- Takeda Pharmaceutical, Japan’s top drugmaker, kept its full-year profit outlook unchanged despite larger-than-forecast first half earnings, as it expects yen strength and weak sales to dull the impact of cost cuts.
